T1	intervention 0 40	Risk Model-Guided Antiemetic Prophylaxis
T2	control 44 62	Physician's Choice
T3	total-participants 543 546	324
T4	eligibility 547 669	patients with early-stage breast cancer undergoing chemotherapy (cyclophosphamide and an anthracycline) for the first time
T5	location 708 714	Ottawa
T7	intervention-participants 810 813	154
T8	control-participants 842 845	170
T10	outcome 1698 1707	no nausea
T11	iv-bin-percent 1709 1714	53.7%
T12	cv-bin-percent 1740 1745	41.6%
T13	outcome 1783 1794	no vomiting
T14	iv-bin-percent 1796 1801	91.8%
T15	cv-bin-percent 1827 1832	82.2%
T16	outcome 1623 1642	In the acute period
T17	outcome 1967 1976	no nausea
T18	iv-bin-percent 1978 1983	39.6%
T19	cv-bin-percent 2009 2014	30.7%
T20	outcome 2051 2062	no vomiting
T21	iv-bin-percent 2064 2069	87.1%
T22	cv-bin-percent 2095 2100	78.0%
T23	outcome 2134 2155	in the delayed period
T6	outcome-Measure 1341 1376	control of both nausea and vomiting
